



CooperVision®

Karen Walsh Appointed to Lead CooperVision Global Professional Affairs

Full Scope Approach Reflects Global Growth and ECP-Centric Focus

SAN RAMON, Calif., October 3, 2023—Responding to its continued global growth and expanding partnerships with eye care professionals (ECPs) worldwide, [CooperVision](#) today announced the creation of a unified, full scope Global Professional Affairs organization. The group will be led by Karen Walsh, MCOptom, PGDip, FAAO, FIACLE, FBCLA, who has been promoted to Senior Director in conjunction with the development.

“ECPs are central to patient prescribing choices and influential advocates whose views and decisions shape the contact lens category. Establishing a singular, ECP-led Global Professional Affairs team will better inform our product development, commercialization strategies, scientific publishing, product support and education outreach,” said Simon Seshadri, Senior Vice President, Global Marketing & Life Cycle Management, CooperVision. “Working hand-in-hand with their regional Professional Affairs colleagues, Karen’s group will help CooperVision colleagues and our customers thrive as the eye care and ocular health sectors evolve.”



Karen Walsh, Senior Director, Global Professional Affairs, CooperVision

Dr. Walsh is a widely recognized ophthalmic opinion leader. Prior to joining CooperVision in 2021, she built international acclaim as an educator, researcher, and author at the Centre for Ocular Research and Education (CORE) at the University of Waterloo. Following a decade working in clinical contact lens-focused practice, she also served with Johnson & Johnson Vision as Professional Affairs Manager for the U.K. & Ireland. Dr. Walsh is a Fellow of the American Academy of Optometry, the International Association of Contact Lens Educators, and the British Contact Lens Association. She also is a member of the U.K. College of Optometrists and holds a post-graduate diploma in clinical optometry from City University, London.

During her CooperVision tenure, Dr. Walsh has been instrumental in translating scientific knowledge into clinical practice for the MyDay[®], clariti[®], Biofinity[®], and Avaira Vitality[™] contact lens brand portfolios, as well as cultivating information and insights from ECPs worldwide to support strategic planning. She has continued to be an in-demand speaker at CooperVision customer events as well as prominent industry conferences.

###

About CooperVision

CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world's leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision

challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.

About CooperCompanies

CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 15,000 with products sold in over 130 countries. For more information, please visit www.coopercos.com.

Media Contact

Mike McDougall, APR, Fellow PRSA, FAAO, McDougall Communications for CooperVision
mike@mcdougallpr.com or +1-585-545-1815